Stage IA - IB Non Small Cell Lung Cancer Clinical Trial
Official title:
Phase I/II Study of the Decrease of Length of Stereotactic Body Radiation Therapy in the Treatment of Stage IA - IB Non Small Cell Lung Cancer (T1N0M0 or T2aN0M0)
Purpose :
Non small cell lung cancer (NSCLC) is among the most common cancers in the werstern world.
Patients with stage I have the most satisfactory outcomes. The gold standard for treatment is
still surgery, but this approach has recently been challenged by hypofractionnated
stereotactic body radiation therapy (SBRT). Therefore, for patients who are not eligible for
surgery due to their significant co-morbidity, or for those who refuse surgical resection,
stereotactic radiotherapy is an efficient practical alternative. SBRT is well tolerated and
efficient, in fact local control rate at 3 years reaches more than 90%. Most of guidelines
recommand a dose between 48 and 60 Gy delivered in 3 at 8 fractions and 3 weeks. Biological
effect depends on the dose distribution in time and decreases when the number of fractions or
length of radiation treatment increase. Decreasing the length of treatment and the interval
between fractions may improve efficiency of treatment and local control rate. Moreover, it
may improve quality of life of patients. Nevertheless, an evaluation of safety of such
shorter treatment course, with a phase I-II clinical study is needed.
Intervention :
Stereotactic Body Radiation Therapy in the treatment of stage IA - IB non small cell lung
cancer (T1N0M0 or T2aN0M0)
Study type : Interventional
Study design : Endpoint classification : safety/efficacy study Intervention model : single
group assignment Masking : open label Primary purpose : treatment
;